GLP-1 Drugs Coverage Strategies for the Public Sector

As Glucagon-like peptide-1 (GLP-1) medications increase in popularity, health plans and employers are facing significant insurance challenges.  

GLP-1s can cost as much as $1,000 per patient per month, fueling a 13-15% rise in prescription drug expenses and comprising over 10% of claims in some employer plans. Many employers are reevaluating coverage, with some scaling back or eliminating it for weight loss amid budget pressures.

In this article, we’ll examine the impact of the soaring costs of GLP-1s on the public sector and how health plans and employers can support employee well-being without depleting their budget.

Innovations in GLP-1 Drugs: Understanding the Surging Demand in the Public Sector

Originally developed for type 2 diabetes management, GLP-1 medications—such as semaglutide and tirzepatide—have driven significant prescription drug spending over the last few years. Key reported benefits of these medications include:

• Significant reductions in body weight
• Reduced risk of cardiovascular events
• Improved metabolic health

A growing body of evidence suggests that by reducing obesity-related comorbidities, GLP-1s could lower overall healthcare expenditures over time. 

The GLP-1 market is entering a phase of acceleration, marked by innovative formulations, expanded therapeutic applications and research developments such as:

• Emergence of oral semaglutides: Pill forms of drugs offer a more accessible, convenient alternative that appeals to needle-averse patients and can potentially lower costs in some cases. Projections indicate that pill forms will continue to reshape the booming GLP-1 market by attracting new users.
• Next-generation drugs that target increased weight loss: New GLP-1 drugs are in late-stage development, targeting multiple gut hormones to achieve even greater weight loss—potentially double that of current options. 
• New research uncovering broader applications for GLP-1s: Scientists are investigating GLP-1s potential in treating heart failure, chronic liver disease, obstructive sleep apnea and substance use disorders.

These innovations are leading to significant upticks in GLP-1 use across the nation. A recent survey from the Gallup National Health and Well-Being Index found that 12.4% of U.S. adults have taken a GLP-1 medication for weight loss. However, the surging demand for these drugs is creating new budget and regulatory challenges for public sector employers and health plans.

Rising Costs, Regulatory Scrutiny and Market Challenges for Public Entities

Skyrocketing GLP-1 utilization is driving increased health spending and premiums, creating intense budget pressure for employers. This impact is heightened for public sector organizations, which typically already face constrained budgets in serving their communities. 

Even as new innovations surge in GLP-1 drugs, challenges persist that introduce financial risk for employers. High dropout rates due to side effects like nausea and gastrointestinal issues have been reported, with some insurers noting that up to half of patients discontinue GLP-1 drug use within 12 weeks. As a result, organizations may struggle to see a return on their investment, both financially and in their workforce’s overall health.

Legal and compliance considerations add complexity. The Americans with Disabilities Act (ADA) views obesity as a potential disability, prompting scrutiny of coverage decisions that might discriminate.  

Regulatory actions are also intensifying. In February 2026, the FDA announced plans to crack down on non-approved compounded GLP-1s, citing safety and efficacy concerns. This follows warning letters to telehealth firms for misleading claims, signaling the end of widespread compounded drugs.

How Public Sector Organizations are Responding to GLP-1 Coverage Challenges

Health plans and employers are at the forefront of responding to this surge, balancing employee demands with fiscal realities. For example, organizations have been taking the following approaches to limit costs amid growing budget pressures:

• Scaling back or eliminating coverage for weight loss: For instance, programs like Medi-Cal have restricted coverage for weight-loss-only use effective January 2026, prioritizing alternatives like diet and exercise. 
• Leveraging a holistic approach: Some public sector organizations are adopting holistic strategies, integrating GLP-1s with lifestyle programs to promote sustainable health outcomes rather than relying solely on medication.
• Negotiating lower costs and broader access: A November 2025 agreement between the U.S. federal government and manufacturers aims to slash prices for Medicare and Medicaid starting April 2026, potentially influencing employer negotiations. Platforms are advocating for broader access, highlighting that tens of thousands still struggle to obtain branded drugs despite easing shortages.

For public sector health plans and employers, the key lies in evidence-based strategies that enhance employee well-being while navigating budgetary concerns, ultimately contributing to a healthier workforce and society.

The Future of GLP-1 Treatment: How Organizations Can Mitigate Financial Risks

Evolving GLP-1 treatments represent a significant shift for public sector health plans. While innovations like oral pills and multi-target therapies could democratize treatment, stakeholders must learn to adapt to manage costs and ensure equitable access.

As the leading specialty insurance broker for the public sector, Alliant is closely tracking the impact of GLP-1 drugs on the public sector and the financial impact of various GLP-1 strategies. For more information on how your organization can balance cost-effective coverage with access to treatments, reach out to an insurance specialist from Alliant today.